Last updated on September 2018

The Efficacy Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Percutaneous Coronary Intervention | Coronary Artery Disease | Platelet Aggregation Inhibitors | Coronary heart disease
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Male and female aged 18-75.
  • Weight 50 kg
  • Patients with coronary atherosclerotic heart disease diagnosed clinically and planned percutaneous coronary intervention
  • Patients with ability and willingness to sign informed consent and adherence to trial protocol.

Exclusion Criteria:

  • Hemorrhagic symptoms (such as hematemesis, melena, severe or recurrent epistaxis, hemoptysis, marked hematuria, gastrointestinal bleeding, or intracranial hemorrhage), or suspected vascular malformations (such as aneurysms), or abnormal bleeding history (such as abnormal hemorrhage attributed to tooth extraction), himself or his immediate family with coagulation or bleeding disorders (such as hemophilia);
  • Acute myocardial infarction within 7 days (acute ST-segment elevation myocardial infarction or acute non-ST-segment elevation myocardial infarction);
  • Patients with suspected aortic dissection;
  • Predicted left main stenosis > 50%;
  • Predicted total number of stents > 3 or number of lesions (> 50% per lesion stenosis) > 2 or number of stents in the same vascular lesion > 2;
  • Patients with negative coronary Computed Tomography angiography CTA (coronary CTA depending on investigator);
  • Patients with severe disease and life expectancy <1 year;
  • Patients with acute peptic ulcer;
  • History of hemorrhagic stroke or history of ischemic stroke within 6 months before screening and a definite diagnosis of structural abnormalities in the central nervous system;
  • Patients with uncontrolled high blood pressure (systolic blood pressure 180 mmHg or diastolic blood pressure 110 mmHg) after drug treatment during screening;
  • One of the following conditions: cardiogenic shock, chronic congestive heart with failure New York Heart Association (NYHA) grade III grade or left ventricular ejection fraction determined by echocardiography < 35%, hypotension (systolic pressure < 90 mmHg and or diastolic pressure < 60 mmHg), severe arrhythmias (including high-degree atrioventricular block, sick sinus syndrome, persistent ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, and hepatic insufficiency (ALT or AST caused by non-cardiac diseases exceeding the upper limit of normal by more than 3 times), severe renal insufficiency (eGFR < 30 ml/min), cirrhosis;
  • Patients receiving intravenous or oral antiplatelet agents (except aspirin), intravenous thrombolytics, and oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) within 14 days before screening;
  • Patients receiving non-steroidal anti-inflammatory drugs (except aspirin) and prostacyclin or other drugs that may affect coagulation and can not be discontinued
  • Prolonged cardiopulmonary resuscitation (more than 10 minutes) or severe trauma within 2 weeks before screening;
  • Plan to undergo other surgery within 1 month after participating in this trial;
  • History of severe allergies, non-allergic drug reactions or allergies to 2 or more drugs (including contrast agents), or known allergies to the similar drugs (clopidogrel, ticagrelor) as the study drug or contraindication of aspirin;
  • Patients with mental disorders or alcohol dependence;
  • Patients being receiving any experimental medicine or experimental medical devices
  • Prothrombin time (PT)> 1.3 times the upper limit of normal or international normalized ratio (INR)> 2.0
  • Platelet count (PLT) < 10010^9/L or > 60010^9/L;
  • Hemoglobin < 10g/dL;
  • Patients who cannot tolerate dual antiplatelet therapy for 28 days
  • Female of reproductive age with positive blood pregnancy test
  • Female with gestational intention or in lactation;
  • Other unsuitable conditions considered by investigators.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.